PT  - JOURNAL ARTICLE
AU  - Henry Surendra
AU  - Ngabila Salama
AU  - Karina D Lestari
AU  - Verry Adrian
AU  - Widyastuti
AU  - Dwi Oktavia
AU  - Rosa N Lina
AU  - Bimandra A Djaafara
AU  - Ihsan Fadilah
AU  - Rahmat Sagara
AU  - Lenny L Ekawati
AU  - Ahmad Nurhasim
AU  - Riris A Ahmad
AU  - Aria Kekalih
AU  - Ari F Syam
AU  - Anuraj H Shankar
AU  - Guy Thwaites
AU  - J. Kevin Baird
AU  - Raph L. Hamers
AU  - Iqbal RF Elyazar
TI  - Pandemic inequity in a megacity: a multilevel analysis of individual, community and health care vulnerability risks for COVID-19 mortality in Jakarta, Indonesia
AID  - 10.1101/2021.11.24.21266809
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.11.24.21266809
4099  - http://medrxiv.org/content/early/2021/11/26/2021.11.24.21266809.short
4100  - http://medrxiv.org/content/early/2021/11/26/2021.11.24.21266809.full
AB  - Background The 33 recognized megacities comprise approximately 7% of the global population, yet account for 20% COVID-19 deaths. The specific inequities and other factors within megacities that affect vulnerability to COVID-19 mortality remain poorly defined. We assessed individual, community-level and health care factors associated with COVID-19-related mortality in a megacity of Jakarta, Indonesia, during two epidemic waves spanning March 2, 2020, to August 31, 2021.Methods This retrospective cohort included all residents of Jakarta, Indonesia, with PCR-confirmed COVID-19. We extracted demographic, clinical, outcome (recovered or died), vaccine coverage data, and disease prevalence from Jakarta Health Office surveillance records, and collected sub-district level socio-demographics data from various official sources. We used multi-level logistic regression to examine individual, community and sub-district-level health care factors and their associations with COVID-19-mortality.Findings Of 705,503 cases with a definitive outcome by August 31, 2021, 694,706 (98·5%) recovered and 10,797 (1·5%) died. The median age was 36 years (IQR 24–50), 13·2% (93,459) were <18 years, and 51·6% were female. The sub-district level accounted for 1·5% of variance in mortality (p<0.0001). Individual-level factors associated with death were older age, male sex, comorbidities, and, during the first wave, age <5 years (adjusted odds ratio (aOR) 1·56, 95%CI 1·04-2·35; reference: age 20-29 years). Community-level factors associated with death were poverty (aOR for the poorer quarter 1·35, 95%CI 1·17-1·55; reference: wealthiest quarter), high population density (aOR for the highest density 1·34, 95%CI 1·14-2·58; reference: the lowest), low vaccine coverage (aOR for the lowest coverage 1·25, 95%CI 1·13-1·38; reference: the highest).Interpretation In addition to individual risk factors, living in areas with high poverty and density, and low health care performance further increase the vulnerability of communities to COVID-19-associated death in urban low-resource settings.Funding Wellcome (UK) Africa Asia Programme Vietnam (106680/Z/14/Z).Evidence before this study We searched PubMed on November 22, 2021, for articles that assessed individual, community, and healthcare vulnerability factors associated with coronavirus disease 2019 (COVID-19) mortality, using the search terms (“novel coronavirus” OR “SARS-CoV-2” OR “COVID-19”) AND (“death” OR “mortality” OR “deceased”) AND (“community” OR “social”) AND (“healthcare” OR “health system”). The 33 recognized megacities comprise approximately 7% of the global population, yet account for 20% COVID-19 deaths. The specific inequities and other factors within megacities that affect vulnerability to COVID-19 mortality remain poorly defined. At individual-level, studies have shown COVID-19-related mortality to be associated with older age and common underlying chronic co-morbidities including hypertension, diabetes, obesity, cardiac disease, chronic kidney disease and liver disease. Only few studies from North America, and South America have reported the association between lower community-level socio-economic status and healthcare performance with increased risk of COVID-19-related death. We found no studies have been done to assess individual, community, and healthcare vulnerability factors associated with COVID-19 mortality risk, especially in lower-and middle-income countries (LMIC) where accessing quality health care services is often challenging for substantial proportions of population, due to under-resourced and fragile health systems. In Southeast Asia, by November 22, 2021, COVID-19 case fatality rate had been reported at 2·2% (23,951/1,104,835) in Vietnam, 1·7% (47,288/2,826,853) in Philippines, 1·0% (20,434/2,071,009) in Thailand, 1·2% (30,063/2,591,486) in Malaysia, 2·4% (2,905/119,904) in Cambodia, and 0·3% in Singapore (667/253,649). Indonesia has the highest number of COVID-19 cases and deaths in the region, reporting 3·4% case fatality rate (143,744 /4,253,598), with the highest number of cases in the capital city of Jakarta. A preliminary analysis of the first five months of surveillance in Jakarta found that 497 of 4265 (12%) hospitalised patients had died, associated with older age, male sex; pre-existing hypertension, diabetes, or chronic kidney disease; clinical diagnosis of pneumonia; multiple (>3) symptoms; immediate intensive care unit admission, or intubation.Added value of this study This retrospective population-based study of the complete epidemiological surveillance data of Jakarta during the first eighteen months of the epidemic is the largest studies in LMIC to date, that comprehensively analysed the individual, community, and healthcare vulnerability associated with COVID-19-related mortality among individuals diagnosed with PCR-confirmed COVID-19. The overall case fatality rate among general population in Jakarta was 1·5% (10,797/705,503). Individual factors associated with risk of death were older age, male sex, comorbidities, and, during the first wave, age <5 years (adjusted odds ratio (aOR) 1·56, 95%CI 1·04-2·35; reference: age 20-29 years). The risk of death was further increased for people living in sub-districts with high rates of poverty (aOR for the poorer quarter 1·35, 95%CI 1·17-1·55; reference: wealthiest quarter), high population density (aOR for the highest density 1·34, 95%CI 1·14-2·58), and low COVID-19 vaccination coverage (aOR for the lowest coverage 1·25, 95%CI 1·13-1·38; reference: the highest).Implications of all available evidence Differences in socio-demographics and access to quality health services, among other factors, greatly influence COVID-19 mortality in low-resource settings. This study affirmed that in addition to well-known individual risk factors, community-level socio-demographics and healthcare factors further increase the vulnerability of communities to die from COVID-19 in urban low-resource settings. These results highlight the need for accelerated vaccine rollout and additional preventive interventions to protect the urban poor who are most vulnerable to dying from COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by the Wellcome (UK) Africa Asia Programme Vietnam (106680/Z/14/Z). The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all of the data and the final responsibility to submit for publication. All authors were not precluded from accessing data in the study, and accepted responsibility to submit for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Health Research Ethics Committee of the National Institute of Health Research and Development, Ministry of Health Indonesia (LB.02.01/2/KE.643/2021). The requirement for patient consent was waived as this was a secondary analysis of anonymised routine surveillance dataI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors